aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Diabetomics is a global medical diagnostics company specializing in non-invasive point-of-care tests for diabetes and pregnancy-related conditions. Their product lineup includes Lumella® for early detection of preeclampsia and gestational diabetes, Glucema® for diabetes monitoring through saliva testing, and Insudex® for early detection of type-1 diabetes and Latent Autoimmune Diabetes in Adults (LADA). These innovative tests aim to provide quick and easy diagnostic solutions for patients and healthcare providers.
The company's focus on non-invasive testing methods represents a significant advancement in diabetes risk management and monitoring. By offering comprehensive blood analyses from a simple finger prick, Diabetomics enables patients with various types of diabetes to effectively manage their blood sugar levels. Their point-of-care solutions contribute to early detection and improved management of diabetes and related conditions, potentially alleviating the burden on patients and healthcare systems.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Diabetes Tests
Technology
Analytics
Tags
Biotech, Healthtech
Model Types
Hardware, Software
Revenue Type(s)
Recurring
Customer Type(s)
Consumers, Enterprise
Geographic Exposure
Global
When was Diabetomics founded?
Diabetomics was founded in 2008.
Where is Diabetomics’s headquarters located?
Diabetomics’s headquarters is located in Hillsboro, OR, US.
When was Diabetomics’s last funding round?
Diabetomics’s most recent funding round was for $2.1M (USD) in January 2018.
How many employees does Diabetomics have?
Diabetomics has 11 employees as of Feb 5, 2024.
How much has Diabetomics raised to-date?
As of July 05, 2023, Diabetomics has raised a total of $12.1M (USD) since Jan 12, 2018.
Add Comparison
Total Raised to Date
$12.1M
USD
Last Update Jan 12, 2018
Last Deal Details
$2.1M
USD
Jan 12, 2018
Series Unknown
Total Employees Over Time
11
As of Feb 2024
Diabetomics Address
2345 Overlook Dr NE
Suite # 140
Hillsboro,
Oregon
97006
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts